Skip to main content

Table 5 Questionnaire-based outcomes in the depression trial

From: Collaborative care for depression and anxiety disorders: results and lessons learned from the Danish cluster-randomized Collabri trials

 

6-months’ follow-up

 

15-months’ follow-up

CC (n = 272)

TAU (n = 53)

P

Effect size

CC (n = 272)

TAU (n = 53)

P

Primary outcome

 BDI-II

13.3 (12.0–14.6)

19.2 (15.6–22.7)

0.002

0.52

11.8 (10.5–13.1)

14.7 (11.0–18.4)

0.138

Secondary outcomes

 BAI

11.0 (10.1–11.9)

14.5 (11.7–17.3)

0.024

 

9.3 (8.3–10.2)

11.6 (8.7–14.4)

0.132

 SCL-90-Ra

59.2 (53.5–65.0)

84.6 (63.4–105.8)

0.024

 

36.1 (30.1–42.2)

40.6 (16.8–64.4)

0.719

 GAF

68.0 (66.3–69.6)

65.2 (61.1–69.3)

0.228

 

71.2 (69.3–73.0)

66.3 (60.1–72.6)

0.149

Explorative outcomes

 The Diagnostic Apathia Scale

3.4 (3.0–3.8)

4.3 (3.5–5.2)

0.062

 

3.1 (2.6–3.5)

3.9 (3.0–4.9)

0.095

 PSP

68.7 (67.2–70.1)

66.9 (62.9–70.8)

0.397

 

71.3 (69.7–72.9)

68.7 (63.2–74.2)

0.383

 SDS

9.5 (8.5–10.6)

11.0 (8.5–13.6)

0.291

 

6.7 (5.5–7.8)

9.1 (5.0–13.2)

0.266

 WHO-5

54.2 (50.7–57.8)

46.7 (40.2–53.2)

0.044

 

54.3 (50.7–58.0)

52.6 (43.5–61.8)

0.738

    Personal Controlb

22.5 (21.9–23.2)

20.5 (18.9–22.1)

0.024

 

22.4 (21.8–23.1)

21.3 (19.9–22.7)

0.141

 Control/Manage Depressionc

6.3 (6.0–6.6)

5.3 (4.5–6.2)

0.033

 

6.2 (5.8–6.6)

5.9 (4.9–6.8)

0.467

 Obtain Help from Community, Family, Friendsc

6.5 (6.2–6.8)

5.2 (4.3–6.1)

0.010

 

6.3 (6.0–6.7)

6.1 (5.3–7.0)

0.697

 EQ-5D-3 L

0.8 (0.8–0.8)

0.7 (0.6–0.8)

0.007

 

0.8 (0.8–0.9)

0.8 (0.7–0.8)

0.174

 PRISEd

14.0 (12.2–15.9)

17.4 (13.5–21.3)

0.132

 

12.4 (10.5–14.4)

16.0 (11.1–20.9)

0.178

 Remission, %

53.9 (47.1–60.7)

39.3 (25.2 53.3)

0.069

 

61.9 (55.2–68.5)

53.5 (37.9–69.1)

0.310

 INSPIRE-S

74.1 (70.1–78.1)

50.3 (37.9–62.7)

< 0.001

 

–

–

 

 INSPIRE-R

84.7 (81.9–87.6)

60.8 (50.9–70.6)

< 0.001

 

–

–

 

 CSQ-8

26.7 (26.0–27.3)

21.6 (19.8–23.3)

< 0.001

 

–

–

 
  1. Abbreviations: BDI-II Beck Depression Inventory-II, BAI Beck Anxiety Inventory, CC Collaborative care, CSQ-8 Client Satisfaction Questionnaire, GAF-F Global Assessment of Functioning, EQ-5D-3L EuroQol Five Dimensions Questionnaire with Three Levels, INSPIRE-S Recovery support from staff (Support), INSPIRE-R Recovery support from staff (Relationship), PRISE Patient Rated Inventory of Side Effects, PSP Personal and Social Performance Scale, SCL-90-R Symptom Checklist-90-Revised, SDS Sheehan Disability Scale, TAU Treatment-as-usual, WHO-5 World Health Organization-5 Well-Being Index
  2. Note: Means are estimated based on imputed data. In BDI-II, BAI, SCL-90-R, SDS, The Diagnostic Apathia Scale, and PRISE, lower scores are associated with a better outcome. In GAF, PSP, WHO-5, Personal control subscale from IPQ-R, Control/manage Depression subscale, Obtain Help from Community, Family, Friends subscale, EQ-5D-3L, CSQ-8, INSPIRE-S, and INSPIRE-R higher scores are associated with a better outcome
  3. a SCL-90-R was modified slightly as a reference period of two weeks was used instead of one week. b Subscale from the Illness Perception Questionnaire-Revised (IPQ-R). c Subscale from the Chronic Disease Self-Efficacy Scales. d Side effects were reported for the proportion of participants who used medication